Form 4: Century Therapeutics CSO Sells Shares for Tax

Century Therapeutics' Chief Scientific Officer, Chad Cowan, reported a disposition of 1,431 common shares to cover tax obligations related to restricted stock unit vesting.

Summary

• Chad Cowan, Chief Scientific Officer of Century Therapeutics, Inc. (IPSC), reported a transaction on March 11, 2026.
• The transaction involved the disposition of 1,431 shares of common stock at a price of $2.73 per share.
• These shares were withheld by the Issuer to satisfy tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Cowan directly beneficially owns 1,177,045 shares of common stock.
• Additionally, 10,697 shares are indirectly beneficially owned by the Cowan Investment Nominee Trust, with Mr. Cowan disclaiming beneficial ownership except for any pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine compliance transaction related to executive compensation rather than a strategic move or a reflection of company performance.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as share dispositions for tax withholding upon RSU vesting, are common across the biotechnology and pharmaceutical industries as part of executive compensation plans. These transactions typically do not reflect a change in management's outlook on the company's prospects but rather a standard operational aspect of equity compensation.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine, non-discretionary transaction for tax purposes, not indicative of a change in insider sentiment or company fundamentals.

Key Dates

Keywords

Century Therapeutics, IPSC, Chad Cowan, Chief Scientific Officer, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, RSU Vesting